Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Human Secretin (CHIROSTIM) on Pancreatic Fluid Composition in Healthy Volunteers
NCT07285863Phase 4Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secretin in exocrine pancreatic insufficiency (EPI) and chronic pancreatitis (CP), sponsored by Mayo Clinic. Primary endpoints: Pancreatic Fluid Bicarbonate Composition at 20 months, Pancreatic Fluid Sodium Composition at 20 months and 2 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
secretin
03
Conditions
exocrine pancreatic insufficiency (EPI)chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT07285863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285863.